Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes.
Aged
Biomarkers, Tumor
/ metabolism
Female
Humans
Mitogen-Activated Protein Kinases
/ metabolism
Phosphatidylinositol 3-Kinase
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Receptor, ErbB-2
/ metabolism
Ribosomal Protein S6 Kinases, 70-kDa
/ metabolism
Signal Transduction
/ physiology
Triple Negative Breast Neoplasms
/ metabolism
Breast cancer intrinsic subtypes
HER2-positive breast cancer
hierarchical clustering
mitogen-activated protein kinase
phosphatidylinositol-3-kinase
triple-negative breast cancer
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
11
06
2019
accepted:
10
01
2020
pubmed:
25
1
2020
medline:
27
5
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
The phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways are frequently activated in breast cancer. We recently demonstrated the importance of analyzing multiple proteins as read-out for pathway activation in ER+/HER2- breast cancer, since single proteins are known to provide insufficient information. Here, we determined pathway activation in other primary breast cancer intrinsic subtypes derived from postmenopausal patients. Tumor blocks were recollected, and immunohistochemistry was performed using antibodies against PTEN, p-AKT(Thr308), p-AKT(Ser473), p-p70S6K, p-4EBP1, p-S6RP(Ser235/236) and p-ERK1/2, followed by unsupervised hierarchical clustering. In 32 ER+/HER2+, 37 ER-/HER2+ and 74 triple-negative breast cancer patients, subgroups were identified with preferentially activated (A) and preferentially not activated (N) proteins. These subgroups likely reflect tumors with differences in biological behavior as well as treatment outcome.
Identifiants
pubmed: 31976581
doi: 10.1111/apm.13026
pmc: PMC7317370
doi:
Substances chimiques
Biomarkers, Tumor
0
Phosphatidylinositol 3-Kinase
EC 2.7.1.137
Receptor, ErbB-2
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Ribosomal Protein S6 Kinases, 70-kDa
EC 2.7.11.1
Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-307Subventions
Organisme : TI Pharma
ID : T3-502
Informations de copyright
© 2020 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology.
Références
Clin Cancer Res. 2015 May 1;21(9):2065-74
pubmed: 25649019
Nat Rev Clin Oncol. 2012 Sep;9(9):529-41
pubmed: 22825374
Pharmgenomics Pers Med. 2014 Aug 06;7:203-15
pubmed: 25206307
Ann Oncol. 2016 Nov;27(11):2059-2066
pubmed: 27573562
Ann Oncol. 2012 Aug;23(8):2034-42
pubmed: 22172323
Curr Mol Pharmacol. 2014;7(1):4-21
pubmed: 25563853
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast. 2018 Oct;41:151-158
pubmed: 30099326
Adv Ther. 2013 Oct;30(10):870-84
pubmed: 24158787
Clin Cancer Res. 2019 Mar 15;25(6):1970-1979
pubmed: 30559169
Lancet Oncol. 2015 Jul;16(7):816-29
pubmed: 26092818
APMIS. 2020 Apr;128(4):298-307
pubmed: 31976581
Lancet Oncol. 2014 May;15(6):580-91
pubmed: 24742739
Breast J. 2009 Nov-Dec;15(6):593-602
pubmed: 19764994
Breast Cancer Res Treat. 2011 Jun;127(2):407-16
pubmed: 20617378
J Cell Biochem. 2018 Jan;119(1):213-222
pubmed: 28513879
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cancer Sci. 2015 Nov;106(11):1582-9
pubmed: 26353837
Biochem Biophys Res Commun. 2017 Aug 5;489(4):484-489
pubmed: 28576487
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Breast Cancer Res. 2014 Jan 21;16(1):R6
pubmed: 24447434
Cancer Treat Rev. 2013 Dec;39(8):935-46
pubmed: 23643661
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
J Clin Oncol. 2013 Jun 10;31(17):2115-22
pubmed: 23650412
Int J Cancer. 2020 Apr 15;146(8):2348-2359
pubmed: 31490549
Ann Oncol. 2017 Feb 1;28(2):313-320
pubmed: 27803006
Sci Rep. 2015 Jan 13;5:7758
pubmed: 25582346
Cancer Epidemiol. 2016 Dec;45:82-90
pubmed: 27770672
Clin Cancer Res. 2016 Jun 1;22(11):2675-83
pubmed: 26758558
Int J Clin Oncol. 2015 Jun;20(3):490-8
pubmed: 25312293
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Oncotarget. 2016 Sep 13;7(37):60712-60722
pubmed: 27474173
J Mammary Gland Biol Neoplasia. 2014 Dec;19(3-4):253-70
pubmed: 25544707
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Breast Cancer Res. 2012 May 23;14(3):R83
pubmed: 22621334
Br J Cancer. 2018 Oct;119(7):832-839
pubmed: 30287915
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
Am J Clin Oncol. 2019 Jul;42(7):588-595
pubmed: 31166208
Cancer Sci. 2007 Dec;98(12):1889-92
pubmed: 17892507
Ann Oncol. 2014 Oct;25(10):1973-9
pubmed: 25009009
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861